Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

ISTH SSC APEX Poster: Efficacy and Safety of Betrixaban for Extended Duration Thromboprophylaxis among Acutely Ill Medical Patients

To access The New England Journal of Medicine publication on the Phase 3 APEX study of betrixaban visit: http://www.nejm.org/doi/full/10.1056/NEJMoa1601747 and NEJM APEX Supplement

Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
Portola Pharmaceuticals Conference Call regarding CRL from FDA for BLA for AndexXa™
Thursday, August 18, 2016 8:30 a.m. ET

Q2 2016 Portola Pharmaceuticals, Inc. Financial Results Conference Call
Tuesday, August 9, 2016 1:30 p.m. PT

Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$20.41
Change (%) Stock is Up 0.36 (1.80%)
Volume2,823,931
Data as of 08/24/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. We are advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhib... More >>

Recent NewsMore >>
DateTitle 
08/19/16Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa™ (andexanet alfa), a Factor Xa Inhibitor Antidote
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that the MAA for IndexXa™ (andexanet alfa; trade name in the United States is AndexXa™), a Factor Xa inhibitor antidote, has been submitted to the EMA, completed the validation period, and has been accepted for review. IndexXa is in development for patients treated with a Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled... 
Printer Friendly Version
08/17/16Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa™ (andexanet alfa)
-- Conference call on August 18 at 8:30 am ET -- SOUTH SAN FRANCISCO, Calif., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for AndexXa™ (andexanet alfa). An FDA-designated Breakthrough Therapy, AndexXa is in development for patients treated with a direct (apixaban, rivaroxaban, or edoxaban) or ... 
Printer Friendly Version
08/09/16Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today provided a corporate update and reported its financial results for the quarter ended June 30, 2016. “We made significant progress in the second quarter to advance our goal of commercializing multiple medicines that could change current medical practices for treating patients with thrombotic disorders and hematological cancers," said Bill Lis... 
Printer Friendly Version
08/02/16Portola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended June 30, 2016, and provide a general business overview on Tuesday, August 9, 2016, at 4:30 p.m. ET (1:30 p.m. PT). Conference Call Details The live conference call on Tuesday, August 9, 2016, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828... 
Printer Friendly Version
06/01/16Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib in... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.